Unraveling Biophysical Interactions of Radiation Pneumonitis in Non-Small-Cell Lung Cancer via Bayesian Network Analysis

Yi Luo, Issam El Naqa, Daniel L. McShan, Dipankar Ray, Ines Lohse, Martha M. Matuszak, Dawn Owen, Shruti Jolly, Theodore S. Lawrence, Feng-Ming Kong, Randall K. Ten Haken

Affiliations of authors: Department of Radiation Oncology, The University of Michigan, Ann Arbor, MI (YL, IEN, DM, DR, IL, MS, MM, DO, SJ, TL, RTH); Department of Radiation Oncology, Indiana University, Indianapolis, IN (FMK)

Correspondence to: Randall K. Ten Haken, PhD, University of Michigan, Department of Radiation Oncology, UH B2C432, SPC 5010, 1500 East Medical Center Dr., Ann Arbor, MI 48109-5010 (e-mail: <u>rth@med.umich.edu</u>; phone: (734) 936-8695; Fax (734) 936-7859)

Appendix E: Mechanistic Biological Interpretation of the Results

Our study of genetic variants identified four SNPs: Rs1800469 (TGF- β 1), Rs4803455 (TGF- β 1), Rs1799983 (NOS3), and Rs6494633 (SMAD3) that were specifically prominent in our dataset. Rs1800469 (-509 C/T) is a SNP within the promoter of polymorphisms of the transforming growth factor beta1 (TGFβ1), a multifunctional growth factor involved in wound healing and radiation pneumonitis [1, 2]. All 49 SNPs in the SMAD3 gene were examined to identify eight haplotype blocks within the gene, and significant associations between haplotypes and overall survival were observed for haplotype block 5 of SMAD3 including Rs6494633 (intron G/A) [3]. SMAD3 is a TGF- β 1-dependent nuclear transcription factor and has been recently described as a key down-stream mediator in fibrotic signaling pathways [4]. In addition to activating extracellular matrix synthesis, SMAD3 appears to mediate the inhibitory activity of TGF-B1 on matrix-degrading enzymes and increase expression of matrix metalloproteinase inhibitors [5]. Additionally, it has been proposed that SMAD3 is up-regulated through a TGF- β 1-dependent pathway and acts as an important transcription factor during the fibrotic process following radiation injury [4]. Moreover, Flanders et al. proposed that SMAD3 plays a unique role in the cellular and tissue responses to wounding, and attenuation of SMAD3 signaling may improve wound healing in previously irradiated skin [6]. Hildebrandt et al. found that Rs1799983 in NOS3 genotype was associated with a 70% reduction in risk of pneumonitis, and their study also demonstrate a dose-related effect in inflammation-related SNPs [7]. Based on the pre-treatment BN data, all the above identified SNPs were primarily negatively associated with dosimetric parameters (Fig. 3a), whose intra-relationships minimally altered even during treatment (Fig. 5*a*). Additionally, during treatment, we have identified a negative association between smad3_Rs6494633 and Interferon-gamma (IFN $_{\Upsilon}$), which impacted RP2 prediction via regulating TGF- β 1 (Fig. 5*a*). Previous study identified a negative correlation between SMAD3 and IFN_{Υ}, where loss of SMAD3 upon genetic ablation caused increased IFN_Y production by natural killers (NK) cells following

treatments with CD-16 and IL-12 [8]. Taken together, these findings support the relationships between SNPs and RP2 identified in our BNs (Figs. 3*a* and 5*a*).

Damage caused by radiotherapy, such as RP, likely results from the interaction between pro- and anti-inflammatory cytokines, whether the inflammation occurs and to what severity depends on the interbalance between these two categories of cytokines [9]. The role of IL-2 in the inflammatory process is complex, and the balance between the IL-2 pro- and anti-inflammatory effects is critical for an appropriate mounting and resolution of immune responses [10]. There is increasing evidence to suggest that IL-15 may play an important role in protective immune responses such as allograft rejection and the pathogenesis of autoimmune diseases, where mononuclear cell infiltration is its hallmark feature [11]. IFN_Y is a cytokine that is produced primarily by activated CD4+ or CD8+ T cells and NK cells and is recognized as chief mediator of innate as well as adaptive immunity[12]. Among the biological activities of IFN_{γ}, activation of macrophages is of key importance and IFN $_{\Upsilon}$ upregulates a variety of pro-inflammatory parameters such as IL-15[13]. Desai et al. have evaluated the cytokines secretion profile of human lung tumor cells, to compare their cytokine profile either before or after acute (6 Gy) and fractionated doses (3×2 Gy), and they observed that the secretion of certain cytokines was cell line-specific and that TGF- β 1 was highly represented in irradiated conditioned medium rather than IFN_{γ}. In addition, in all the cell lines studied, they showed that TGF-β1 increased markedly in a dose dependent manner[14, 15]. These findings corroborate the interactions found among dosimetric information, pre- and during cytokines shown in our BN (Fig. 5a). Moreover, our previous work demonstrated that patients who developed RP2 following radiotherapy had higher plasma TGF-B1 levels compared with those prior to radiotherapy, unlike patients who did not develop RP2 [16], confirming the relatioship between SLP_TGF_β1 and RP2 observed in the BN at mid-treatment timepoint.

Furthermore, our study of genetic expression parameters identified two microRNAs (miR-223-3p and miR-191-5p) as upstream regulators of various cytokines. Both of them are among the top 25 microRNA up-regulated in non-muscle-invasive Bladder Cancer according to white blood cells (WBC)-

derived bio-specimen source[17]. Liang et al. showed that miR-223 overexpression down-regulates ATM expression and sensitizes U87 cells to radiation in vitro and in vivo[18]. In contrast, miR-223 is upregulated in T cell acute lymphocytic leukemia (T-ALL), Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma, and metastatic gastric cancer [19]. Mir-191 is one of the highly expressed and stable miRNA in human serum or saliva [20]. It has been found to be differentially expressed in lung cancer patients; however, it was shown to not alter cell cycle, proliferation or chemo-sensitivity of lung cancer cell lines[21, 22]. In the context of inflammatory response, miR-191 has been shown to be involved in human NK cell activation through IL-2 and IL-15 stimulations[23]; and this relationship is also captured in the BNs (Figs.

3*a* and 5*a*).

References

1. Azhar M, Yin M, Bommireddy R, *et al.* Generation of mice with a conditional allele for transforming growth factor beta 1 gene. Genesis 2009;47(6):423-31.

2. Lu Y, Boer JM, Barsova RM, *et al.* TGFB1 genetic polymorphisms and coronary heart disease risk: a meta-analysis. BMC Med Genet 2012;13:39.

3. Lin M, Stewart DJ, Spitz MR, *et al.* Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. Carcinogenesis 2011;32(7):1050-1056.

4. Lee JW, Zoumalan RA, Valenzuela CD, *et al.* Regulators and mediators of radiation-induced fibrosis: Gene expression profiles and a rationale for Smad3 inhibition. Otolaryngol Head Neck Surg 2010;143(4):525-30.

5. Flanders KC, Major CD, Arabshahi A, *et al.* Interference with transforming growth factor-beta/ Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. Am J Pathol 2003;163(6):2247-57.

6. Flanders KC, Major CD, Arabshahi A, *et al.* Interference with Transforming Growth Factor- β / Smad3 Signaling Results in Accelerated Healing of Wounds in Previously Irradiated Skin The American Journal of Pathology 2003;163(6):2247-57.

7. Hildebrandt MA, Komaki R, Liao Z, *et al.* Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One 2010;5(8):e12402.

8. Trotta R, Dal Col J, Yu J, *et al.* TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells. J Immunol 2008;181(6):3784-92.

9. Guo CX, Wang J, Huang LH, *et al.* Impact of single-nucleotide polymorphisms on radiation pneumonitis in cancer patients. Mol Clin Oncol 2016;4(1):3-10.

10. Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 2008;31(1):7-12.

11. Perera LP. Interleukin 15: its role in inflammation and immunity. Arch Immunol Ther Exp (Warsz) 2000;48(6):457-64.

12. Muhl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. Int Immunopharmacol 2003;3(9):1247-55.

13. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol 1996;156(2):735-41.

14. Desai S, Kumar A, Laskar S, *et al.* Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013;61(1):54-62.

15. Di Maggio FM, Minafra L, Forte Gl, *et al.* Portrait of inflammatory response to ionizing radiation treatment. Journal of Inflammation-London 2015;12.

16. Anscher MS, Kong FM, Andrews K., *et al.* Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-1035.

17. Armstrong DA, Green BB, Seigne JD, *et al.* MicroRNA molecular profiling from matched tumor and bio-fluids in bladder cancer. Mol Cancer 2015;14(1):194.

18. Liang L, Zhu J, Zaorsky NG, *et al.* MicroRNA-223 enhances radiation sensitivity of U87MG cells in vitro and in vivo by targeting ataxia telangiectasia mutated. Int J Radiat Oncol Biol Phys 2014;88(4):955-60.

19. R. Moles MB, C Nicot. STAT1: A Novel Target of miR-150 and miR-223 Is Involved in the Proliferation of HTLV-I–Transformed and ATL Cells. Neoplasia 2015;17:449-462.

20. Patel RS, Jakymiw A, Yao B, *et al.* High resolution of microRNA signatures in human whole saliva. Archives of Oral Biology 2011;56(12):1506-1513.

21. Volinia S, Calin GA, Liu CG, *et al.* A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103(7):2257-61.

22. Patnaik SK, Kannisto E, Yendamuri S. Overexpression of MicroRNA miR-30a or miR-191 in A549 Lung Cancer or BEAS-2B Normal Lung Cell Lines Does Not Alter Phenotype. Plos One 2010;5(2).

23. Liu X, Wang Y, Sun Q, *et al.* Identification of microRNA transcriptome involved in human natural killer cell activation. Immunol Lett 2012;143(2):208-17.